Loading chat...
GA HR998
Resolution
Status
Engrossed
4/1/2022
Primary Sponsor
Sharon Cooper
Click for details
AI Summary
- Georgia House of Representatives expresses support for awareness, education, and understanding of biomarker testing as a tool for personalized diagnosis, treatment, and monitoring of patients
- An estimated 58,970 Georgians will be diagnosed with cancer and 18,970 will die from cancer in 2022, according to the American Cancer Society
- Barriers to biomarker testing contribute to racial, ethnic, and socioeconomic disparities, with Black, older, and Medicaid-insured patients less likely to receive next-generation sequencing biomarker testing
- Patients with certain lung cancers who received biomarker testing experienced a 28 percent reduction in mortality, and 60 percent of treatments in preclinical development rely on biomarker data
- Resolution is non-binding and directs the Clerk of the House to make copies available for public and press distribution
Legislative Description
General Assembly; biomarker testing as a necessary part of precision medicine; recognize benefits
Last Action
House Passed/Adopted
4/1/2022
Committee Referrals
Health and Human Services3/15/2022
Full Bill Text
No bill text available